Regentis Announces Four-Year Exclusive GelrinC Distribution Agreement in Israel
Regentis Biomaterials has appointed AMI Medical Technologies as the exclusive Israeli distributor of GelrinC under a four-year agreement that includes minimum purchase requirements.
Regentis Biomaterials Ltd. has announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for GelrinC, its hydrogel implant for repairing damaged knee cartilage, in Israel. The agreement includes minimum purchase requirements, while Regentis expects initial revenue contributions to begin during 2027.
Under the agreement, AMI will handle the distribution of GelrinC in Israel. Regentis said the distributor will draw on established relationships with orthopaedic surgeons, hospitals and clinics across the country.
AMI, founded in 1986, distributes advanced medical technologies in Israel and represents medical device manufacturers including Stryker. Its activities include orthopaedic products, sports medicine, knee and joint replacement, surgical robotics, clinical training, technical support and implementation services.
GelrinC has approval from Israel’s Ministry of Health through an AMAR medical device registration certificate. The Israeli approval covers the same indication approved in Europe and being pursued in the United States.
Regentis and AMI plan to work with Israel’s leading Health Maintenance Organizations to establish reimbursement coverage and support use of GelrinC by orthopaedic surgeons treating focal cartilage defects.
Until that coverage is in place, the announcement says many Israeli patients may be able to access GelrinC through their private health insurance. The transaction carries further terms that are not set out in this article.
Regentis describes GelrinC as a cell-free, off-the-shelf hydrogel implant designed to treat painful injuries affecting focal articular knee cartilage. The company says the implant is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage through a controlled process.
GelrinC is also being evaluated in a pivotal US Food and Drug Administration study. Regentis said the study had completed over 50% enrollment and described the US programme as a pivotal Phase III clinical programme.
Regentis’ expectations for the timing and amount of revenue from Israel, the extent of AMI’s purchases, the establishment of reimbursement pathways and the progress of the US clinical programme are forward-looking matters subject to uncertainties and assumptions.
The company identified risks including clinical results, regulatory approval, market acceptance, reimbursement, competing therapies, product demand and future financing needs. It also noted that GelrinC’s potential benefits and performance, as well as the timing and results of its development programme, may not develop as anticipated.
Regentis Biomaterials Ltd. announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialisation of GelrinC in Israel. AMI will serve as Regentis’ exclusive distributor and the agreement includes minimum purchase requirements.
Regentis Biomaterials Ltd. announced the agreement on November 9, 2026. The agreement covers the commercialisation of GelrinC in Israel for four years.
AMI Medical Technologies Ltd. will be Regentis Biomaterials Ltd.’s exclusive distributor of GelrinC in Israel. AMI is described as an established Israeli medical technology distributor with an orthopaedic sales and distribution network.
Regentis Biomaterials Ltd. said it expects initial revenue contributions from the agreement to begin in 2027. The company linked this expectation to the agreement’s minimum purchase commitments.
The agreement includes minimum purchase requirements for AMI. Regentis Biomaterials Ltd. did not state the quantity or value of those requirements in the announcement.
AMI will use its relationships with orthopaedic surgeons, hospitals and clinics throughout Israel to support GelrinC’s commercial introduction. AMI also provides clinical training, technical support and implementation services to healthcare providers.
Regentis Biomaterials Ltd. and AMI will collaborate to establish reimbursement coverage for GelrinC with Israel’s leading Health Maintenance Organisations. Until that coverage is in place, the announcement says many Israeli patients may be able to access GelrinC through private health insurance.
GelrinC has regulatory approval from Israel’s Ministry of Health through an AMAR medical device registration certificate. The approval is for the same indication approved in Europe and being pursued in the United States.
GelrinC is Regentis Biomaterials Ltd.’s cell-free, off-the-shelf hydrogel implant for repairing damaged knee cartilage. The company describes it as a product for painful and debilitating injuries to focal articular knee cartilage, with the implant designed to erode and resorb in the knee while surrounding cells regenerate cartilage.
GelrinC is being evaluated in a pivotal US Food and Drug Administration study, which has completed over 50% enrollment. Regentis Biomaterials Ltd. said it is continuing to advance this pivotal Phase III clinical programme in the United States.
Regentis Biomaterials Ltd. describes itself as a regenerative medicine company focused on tissue repair solutions, initially in orthopaedic treatments. Its Gelrin platform is based on synchronised, degradable hydrogel implants intended to regenerate damaged or diseased tissue, including cartilage and bone.
Regentis Biomaterials Ltd. is identified in the announcement as listed on the NYSE American under the ticker symbol RGNT.
Regentis Biomaterials Ltd. identifies risks including the ability of its clinical trials to demonstrate safety and efficacy, the timing and results of clinical studies, regulatory approval, market acceptance, reimbursement pathways, competing therapies, demand and future financing needs. The company also states that the timing and extent of AMI’s purchases and the timing and amount of any Israeli revenue are forward-looking matters subject to uncertainties and assumptions.